Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Revance Therapeutics (RVNC) Reports Q2 Loss of $0.86/Share
August 5, 2019 4:35 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.86), versus ($0.94) reported last year. Revenue for the quarter came in at $0 , versus $686 thousand reported last year.
2019 Financial Outlook
Revance reiterates its financial guidance provided in February 2019. Revance expects 2019 GAAP operating expense to be in the... More